September 15, 2022
The Second Circuit on Thursday affirmed a lower court's decision rebuffing biotechnology company Amyris' arbitration bid in cannabinoid maker Lavvan's $881 million patent and trade secrets suit over cannabis development, ruling that a research agreement between the companies doesn't clearly warrant the arbitration.
July 26, 2021
A New York federal judge on Monday denied biotech company Amyris' bid to arbitrate an $881 million trade secrets fight with cannabinoid manufacturer Lavvan, finding that a prior agreement the parties entered into requires them to litigate intellectual property disputes.
October 06, 2020
Biotech company Amyris Inc. says cannabinoid manufacturer Lavvan Inc. should be forced to arbitrate its claims in an $881 million trade secrets lawsuit between the companies, or the suit should be tossed altogether.
September 10, 2020
A cannabinoid manufacturer slapped biotech company Amyris with an $881 million trade secrets suit Thursday, alleging the company inked a research and development agreement to boost its stock price and then reneged on the terms to conceal a "rotten" business model.